Background
We evaluated HIV antibody (Ab) responses elicited by immunization, in a phase I/II placebo-controlled double blind trial using multiclade, multigene HIV-1-DNA prime boosted with HIV-MVA conducted among healthy volunteers in Tanzania (HIVIS03).
Methods
Sixty HIV-uninfected volunteers, randomized into groups of 20 received placebo or 1 mg HIV-DNA intradermally (id) or 3.8 mg intramuscularly (im). DNA plasmids containing HIV-1 gp160 subtypes A, B, C; rev B; p17/p24 gag A, B and RTmut B were given at months 0, 1 and 3 using a needle-free Biojector device. HIV-MVA expressing CRF01_AE HIV-1 env, gag, pol was administered im by needle at months 9 and 21. Sera were tested at baseline, two months post-first and four weeks post-second HIV-MVA boosting. HIV Ab responses were tested using pseudoviruses and TZM-bl cells as well as luciferaseexpressing infectious molecular clones (IMC-LucR) in PBMC-based assays. ADCC responses were tested using the flow cytometry GranToxiLux-based assay.
Results
Neutralizing Ab activity was demonstrated only in the PBMC assay, and after the second MVA boost in 24 (83%) of 29 vaccinees against the clade CRF01_AE CM235 IMC and in 21 (72%) of 29 vaccinees against clade B SF162-IMC. NK cell depletion from PBMC targets resulted in a significant loss of HIV inhibition by vaccinee sera, indicating a role of Ab-mediated Fcγ-receptor function. Vaccine-induced ADCC responses were detected in 21 (75%) of 28 vaccinees after the second HIV-MVA boost. ADCC Ab titers did not differ significantly between id-(median 840, range 300-5400) and imprimed (median 880, range 400-3600) vaccinees (p=0.45).
Conclusion
HIV-DNA priming followed by two HIV-MVA boosts elicited HIV-specific inhibitory and/or ADCC-mediating antibody responses in a high proportion of Tanzanian adults.
